in

Industry Update: Cannabidiol On the Road to FDA Approval video



Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, provides an update on the status of Epidiolex(R), GW’s cannabidiol product, after positive results from several controlled trials were presented at the 2016 American Epilepsy Society Annual Meeting in Houston, TX.

Go here to read about positive trial results for cannabidiol in Lennox-Gastaut and Dravet syndrome: http://www.neurologyadvisor.com/aes-2016-coverage/cannabidiol-helps-reduce-frequency-of-drop-seizures-in-lennox-gastaut-syndrome/article/576842/
http://www.neurologyadvisor.com/aes-2016-coverage/cannabidiol-reduces-seizure-frequency-in-refractory-dravet-syndrome/article/576878/

For more coverage of AES 2016, go here: http://www.neurologyadvisor.com/aes-2016-coverage/section/7080/

Likes: 1.

This video clip has been viewed: 564 times and provides a duration of 00:02:52 seconds.

What do you think?

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Loading…

0

Comments

0 comments

The Science of CBD with Dr. John Hicks

The Science of CBD with Dr. John Hicks video

Full E-book  The CBD Handbook: Over 100 Recipes for Hemp-Derived Health and Wellness  Review

Full E-book The CBD Handbook: Over 100 Recipes for Hemp-Derived Health and Wellness Review video